MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53

MDM2, a ubiquitin ligase, suppresses wild type TP53 via proteasome-mediated degradation. We evaluated the prognostic and therapeutic value of MDM2 in ovarian clear cell carcinoma. MDM2 expression in ovarian cancer tissues was analyzed by microarray and real-time PCR, and its relationship with progno...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Makii, Chinami, Oda, Katsutoshi, Ikeda, Yuji, Sone, Kenbun, Hasegawa, Kosei, Uehara, Yuriko, Nishijima, Akira, Asada, Kayo, Koso, Takahiro, Fukuda, Tomohiko, Inaba, Kanako, Oki, Shinya, Machino, Hidenori, Kojima, Machiko, Kashiyama, Tomoko, Mori-Uchino, Mayuyo, Arimoto, Takahide, Wada-Hiraike, Osamu, Kawana, Kei, Yano, Tetsu, Fujiwara, Keiichi, Aburatani, Hiroyuki, Osuga, Yutaka, Fujii, Tomoyuki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342744/
https://ncbi.nlm.nih.gov/pubmed/27659536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12175
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak